The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurodegenerative Disorder Therapeutics Market Research Report 2025
Synopsis
The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease.
The global Neurodegenerative Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disorder Therapeutics.
Report Scope
The Neurodegenerative Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd
Segment by Type
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
Segment by Application
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The goal of therapeutic development for neurodegenerative disorders is to develop drugs that slow down or stop the neurodegenerative process. So-called neuroprotective, or disease-modifying, therapies would not only treat the symptoms but slow the continued loss of neurons in disease.
The global Neurodegenerative Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Disorder Therapeutics.
Report Scope
The Neurodegenerative Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen, Inc.
Pfizer, Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
F. Hoffmann- La Roche Ltd.
H. Lundbeck
Merck KGaA
GlaxoSmithKline PLC
AbbVie Inc.
Bristol Myers Squibb Company
Boehringer Ingeiheim International GmbH
Bayer AG
Eisai Co., Ltd
Segment by Type
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
Segment by Application
Multiple Sclerosis
Parkinson'S Disease
Alzheimer'S Disease
Spinal Muscular Atrophy
Huntington Disease
Other Neurodegenerative Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunomodulators
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disorder Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Multiple Sclerosis
1.3.3 Parkinson'S Disease
1.3.4 Alzheimer'S Disease
1.3.5 Spinal Muscular Atrophy
1.3.6 Huntington Disease
1.3.7 Other Neurodegenerative Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2019-2030)
2.2 Neurodegenerative Disorder Therapeutics Growth Trends by Region
2.2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Neurodegenerative Disorder Therapeutics Market Dynamics
2.3.1 Neurodegenerative Disorder Therapeutics Industry Trends
2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disorder Therapeutics Revenue
3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2023
3.5 Neurodegenerative Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disorder Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2025-2030)
5 Neurodegenerative Disorder Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
6.2 North America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
9.2 Latin America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Detail
11.1.2 Biogen, Inc. Business Overview
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.1.5 Biogen, Inc. Recent Development
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Detail
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.2.5 Pfizer, Inc. Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.3.5 Novartis AG Recent Development
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Detail
11.4.2 Sanofi S.A. Business Overview
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.4.5 Sanofi S.A. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 UCB S.A.
11.6.1 UCB S.A. Company Detail
11.6.2 UCB S.A. Business Overview
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.6.5 UCB S.A. Recent Development
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Detail
11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.7.5 F. Hoffmann- La Roche Ltd. Recent Development
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Detail
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.8.5 H. Lundbeck Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Detail
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.9.5 Merck KGaA Recent Development
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Detail
11.10.2 GlaxoSmithKline PLC Business Overview
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.10.5 GlaxoSmithKline PLC Recent Development
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Detail
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.11.5 AbbVie Inc. Recent Development
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Detail
11.12.2 Bristol Myers Squibb Company Business Overview
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.12.5 Bristol Myers Squibb Company Recent Development
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Detail
11.13.2 Boehringer Ingeiheim International GmbH Business Overview
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.13.5 Boehringer Ingeiheim International GmbH Recent Development
11.14 Bayer AG
11.14.1 Bayer AG Company Detail
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.14.5 Bayer AG Recent Development
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Detail
11.15.2 Eisai Co., Ltd Business Overview
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2019-2024)
11.15.5 Eisai Co., Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
